H.C. Wainwright lowered the firm’s price target on Nuvectis Pharma (NVCT) to $10 from $15 and keeps a Buy rating on the shares. The firm removed NXP800 from its projections. The deprioritization of NXP800 allows Nuvectis to better deploy capital in assets with a greater chance of success in the clinic, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCT:
- Strategic Focus on NXP900 Drives Buy Rating for Nuvectis Pharma
- Nuvectis Pharma provides final clinical data update from NXP800 Phase 1b study
- Promising Potential of NXP900 in Combination Therapy for Resistant Lung Cancer Justifies Buy Rating
- Promising Developments in Nuvectis Pharma’s NXP900 Boost Buy Rating
- Nuvectis Pharma’s NXP900 shows positive drug interaction results in lung cancer